Patents Assigned to Institute of Materia Medica, Chinese Academy of Sciences
-
Patent number: 11939386Abstract: Disclosed are a new AXL-targeting monoclonal antibody and antibody-drug conjugate. Also disclosed is a method for preparing said antibody and antibody-drug conjugate. The AXL antibody of the present invention can bind with purified human AXL protein and multiple AXL on tumor cell surface with high effectiveness and high specificity. Said humanized antibody also has high affinity and low immunogenicity. Said AXL antibody-drug conjugate has markable performance against tumors having high AXL expression.Type: GrantFiled: May 10, 2019Date of Patent: March 26, 2024Assignee: Shanghai Institute of Materia Medica, Chinese Academy of SciencesInventors: Ke Yu, Jingkang Shen, Tao Meng, Jinpeng Pei, Lanping Ma, Xin Wang, Rui Jin, Zhiyan Du, Lin Chen, Ting Yu, Yongliang Zhang
-
Patent number: 11919923Abstract: The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia (COVID-19) and other related diseases caused by 2019 novel coronavirus infection.Type: GrantFiled: April 16, 2021Date of Patent: March 5, 2024Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Wuhan Institute of Virology, Chinese Academy of Science, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Vigonvita Life Sciences Co., Ltd.Inventors: Yuanchao Xie, Gengfu Xiao, Yang He, Leike Zhang, Haji Akber Aisa, Hualiang Jiang, Jingshan Shen
-
Publication number: 20240033244Abstract: A YTH N6-Methyladenosine RNA Binding Protein 1 (YTHDF1) attenuating agent, with a compound, and when bound to YTHDF1, the compound binds to amino acid residues 372-392, 479-494 and 526-535 of SEQ ID NO: 1. A modified antigen presenting cell (mAPC), with the mAPC being treated with a YTHDF1 attenuating agent. A composition, with a YTHDF1 attenuating agent, a mAPC treated with the YTHDF1 attenuating agent, and optionally a pharmaceutically acceptable carrier. A method for attenuating an activity of YTHDF1, by administering an effective amount of a YTHDF1 attenuating agent. A method for determining whether or not a candidate agent is a YTHDF1 attenuating agent, by contacting the candidate agent with a YTHDF1 mutant. A method for treating a disease, disorder or condition associated with an expression of an antigen in a subject in need thereof.Type: ApplicationFiled: July 8, 2021Publication date: February 1, 2024Applicants: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, HANGZHOU LEADING EDGE PHARMACEUTICAL LTD., SHANGHAI KANGQIAN BIOTECHNOLOGY LIMITEDInventors: Cheng LUO, Meng XU, Shijie CHEN, Yilin LI, Yantao CHEN, Hualiang JIANG, Kaixian CHEN, Zhanpeng JIANG
-
Patent number: 11873292Abstract: The present invention relates to the fields of medicinal chemistry and pharmacotherapy, and specifically relates to the chemical compound of formula (I), and its racemate, R-isomer, S-isomer, pharmaceutically acceptable salt, and mixtures thereof, as well as its method for preparation, a pharmaceutical composition containing said chemical compound, and use as a lysine-specific demethylase 1 (LSD 1) inhibitor. The cyclopropylamine chemical compound to which the present invention relates may be used in the treatment of cancer.Type: GrantFiled: June 2, 2017Date of Patent: January 16, 2024Assignee: Shanghai Institute of Materia Medica, Chinese Academy of SciencesInventors: Hong Liu, Jia Li, Wei Zhu, Yubo Zhou, Jiang Wang, Mingbo Su, Shuni Wang, Wei Xu, Chunpu Li, Weijuan Kan, Hualiang Jiang, Kaixian Chen
-
Patent number: 11834432Abstract: Provided in the present invention are a substituted amino six-membered nitric heterocyclic ring compound and a preparation and use thereof. In particular, provided in the present invention is a compound as shown by general formula (I) below, wherein the definition of each group is as described in the description. The compound of the present invention has an excellent tyrosine kinase inhibitory activity, and can thus be used to prepare a series of medicines for treating diseases related to tyrosine kinase inhibitory activity.Type: GrantFiled: February 17, 2017Date of Patent: December 5, 2023Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCESInventors: Ao Zhang, Meiyu Geng, Li Xing, Jing Ai, Zilan Song, Xia Peng, Wangting Gu, Jian Ding
-
Publication number: 20230312584Abstract: A salt of nucleoside analog, and crystal form, pharmaceutical composition and use thereof. The salt of nucleoside analog has a structure shown in formula I, wherein X is hydrogen or deuterium; Y is an acid, n is 0.5 to 2, or n is 1. When X is hydrogen or deuterium, Y is hydrogen bromide, and n is 1, the salt of the nucleoside analog exists in the form of a crystal with crystal form I or crystal form A or exists in an amorphous form.Type: ApplicationFiled: October 21, 2021Publication date: October 5, 2023Applicants: VIGONVITA LIFE SCIENCES CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCESInventors: Jingshan SHEN, Yuanchao XIE, Leike ZHANG, Gengfu XIAO, Zhen WANG, Hualiang JIANG, Huaqiang XU, Tianwen HU, Guanghui TIAN
-
Patent number: 11731965Abstract: The present invention provides a tetrahydroprotoberberine compound represented by the formula (I), enantiomers, diastereomers, racemates and mixtures thereof, and pharmaceutically acceptable salts, crystalline hydrates and solvates thereof. The invention also provides a method for preparing the compound and the use thereof in the preparation of a medicament for preventing and/or treating central nervous system diseases.Type: GrantFiled: August 14, 2018Date of Patent: August 22, 2023Assignees: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, TOPHARMAN SHANGHAI CO., LTD.Inventors: Yang He, Xiangrui Jiang, Jianfeng Li, Yu Wang, Zhen Wang, Weiming Chen, Fuqiang Zhu, Chunhui Wu, Rongxia Zhang, Jingshan Shen, Hualiang Jiang
-
Patent number: 11730742Abstract: Disclosed is use of a thieno[3,2-d]pyrimidin-4-one compound represented by general formula (I). Definition of each substituent is as stated in the description and claims, and the compound is used for preparing medicines for treating and/or preventing liver fibrosis and related diseases or preparing a DPP-4 inhibitor, or is used as a DPP-4 inhibitor.Type: GrantFiled: March 8, 2019Date of Patent: August 22, 2023Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCESInventors: Hong Liu, Jia Li, Jiang Wang, Yi Zang, Jian Li, Jingya Li, Dandan Sun, Hualiang Jiang, Kaixian Chen
-
Patent number: 11591325Abstract: The present invention provides a 2-polysubstituted aromatic ring-pyrimidine derivative and an optical isomer thereof, or a pharmaceutically acceptable salt or solvate thereof, the compound, and an optical isomer thereof or a pharmaceutically thereof acceptable salts or solvates can be used in the preparation of anti-tumor drugs. The invention designs and synthesizes a series of novel small molecule Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained by structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess potent anticancer activity, Chk1 kinase inhibitory activity, and are promising Chk1 inhibitors, and can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.Type: GrantFiled: November 8, 2017Date of Patent: February 28, 2023Assignees: ZHEJIANG UNIVERSITY, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCESInventors: Tao Liu, Jia Li, Yongzhou Hu, Yubo Zhou, Xiaowu Dong, Anhui Gao, Pinrao Song, Peipei Wang, Lexian Tong, Xiaobei Hu, Mingbo Su
-
Patent number: 11555009Abstract: The invention provides 2-(substituted phenylhetero) aromatic formate FTO inhibitors, a preparation method thereof, and applications thereof. Specifically, disclosed in the present invention are a 2-(substituted phenylhetero) aromatic formate compound represented by the following formula (I), and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, which can be used as an FTO targeting inhibitor for treating diseases associated with FTO targets, including obesity, metabolic syndrome (MS), type 2 diabetes (T2D), Alzheimer's diseases, and cancers such as breast cancers, small-cell lung cancers, human bone marrow rhabdomyosarcoma, pancreatic cancer, malignant glioblastoma and the like.Type: GrantFiled: March 1, 2018Date of Patent: January 17, 2023Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCESInventors: Caiguang Yang, Yue Huang, Ze Dong, Tao Zhang, Hongjiao Xu
-
Patent number: 11534495Abstract: A tissue factor (TF)-targeted antibody-drug conjugate (ADC) and a method for preparing the ADC. The ADC is capable of binding to TF antigen with high specificity, and has high affinity, low immunogenicity, high cytotoxicity, and significant anti-tumor activity.Type: GrantFiled: June 9, 2017Date of Patent: December 27, 2022Assignees: FUDAN UNIVERSITY, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SHANGHAI MIRACOGEN INC.Inventors: Ke Yu, Jingkang Shen, Tao Meng, Lanping Ma, Xuesai Zhang, Qingrou Li, Qing Lin
-
Publication number: 20220395476Abstract: Provided are a drug for treating artery-related diseases and the use thereof. Specifically, provided are the use of a class of compounds of formula I in the treatment of artery-related diseases. Experiments show that the compounds of formula I have a significant effect on aneurysm, intramural hematoma and/or atrerial dissection.Type: ApplicationFiled: September 29, 2020Publication date: December 15, 2022Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCESInventors: Baohong JIANG, Xianjing ZHANG, Yuchao DING, Ziyi ZHAI
-
Patent number: 11498927Abstract: The present invention relates to a heterocyclic amide inhibiting RIP1 kinase and the use thereof, and specifically, to a compound of formula I, its pharmaceutically acceptable salts, stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, polymorphs, solvates or isotopically labeled compounds, a pharmaceutical composition comprising the compound, and the pharmaceutical use thereof. The compound is particularly effective for treatment of diseases or disorders mediated by RIP1 kinase.Type: GrantFiled: October 8, 2019Date of Patent: November 15, 2022Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCESInventors: Bing Zhou, Wei Tang, Xiangbo Yang, Huimin Lu, Mengying Gao, Yaxi Yang, Huijin Feng
-
Patent number: 11465984Abstract: The invention relates to a compound of formula (I): wherein variables are as defined in the specification. The compound is an inhibitor of an ERK kinase, e.g. ERK1 and/or ERK2 kinase. The invention also relates to the use of the compound and a method for preparing the compound, and a pharmaceutical composition containing the compound.Type: GrantFiled: September 29, 2018Date of Patent: October 11, 2022Assignees: SHANGHAI HAIHE PHARMACEUTICAL CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCESInventors: Lei Li, Meiyu Geng, Ying Huang, Jian Ding, Qiong Zhang, Min Huang, Shuai Tang, Ning Shen, Yi Chen
-
Patent number: 11464795Abstract: Provided are use of a saponin compound of formula (I) or (II), or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament targeting PD-1. The medicament targeting PD-1 is one which treats a disease by inhibiting PD-1 from binding to a ligand thereof. The disease may be a tumor, an infection caused by a bacterium, a virus or a fungus, or an inflammatory disease.Type: GrantFiled: July 12, 2018Date of Patent: October 11, 2022Assignees: East China University Of Science And Technology, Yunnan University, Shanghai Institute of Materia Medica, Chinese Academy of SciencesInventors: Honglin Li, Weilie Xiao, Lili Zhu, Lina Quan, Qiao Li, Yanyan Diao, Zhenjiang Zhao, Hualiang Jiang
-
Patent number: 11464794Abstract: The present invention relates to an alginic oligosaccharic diacid composition comprising a mannuronic diacid of Formula (IV) or a pharmaceutically acceptable salt thereof, wherein n is an integer selected from 1 to 9, m is selected from 0, 1 or 2, m? is selected from 0 or 1, and wherein the total weight of alginic oligosaccharic diacid wherein n=1-5 accounts for more than 60% of the total weight of the composition; the total weight of guluronic acids accounts for less than 50% of the total weight of the composition.Type: GrantFiled: June 28, 2019Date of Patent: October 11, 2022Assignees: GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCESInventors: Meiyu Geng, Zhenqing Zhang, Yingshen Jin, Zhongping Xiao, Jian Ding
-
Patent number: 11434226Abstract: The present disclosure relates to a salt of phenyl pyrimidinone compound, a polymorph thereof and a pharmaceutical composition comprising the same and a use thereof, particularly relates to the hydrochlorate of phenyl pyrimidinone compound of following formula (I-A) and a pharmaceutically acceptable polymorph, solvate, hydrate, co-crystal, anhydrous substance, or amorphous form thereof, a pharmaceutical composition and a pharmaceutical unit dosage comprising the same, the preparing method and use thereof.Type: GrantFiled: January 7, 2020Date of Patent: September 6, 2022Assignees: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SUZHOU VIGONVITA LIFE SCIENCES CO., LTD., TOPHARMAN SHANGHAI CO., LTD.Inventors: Jingshan Shen, Yang He, Weiming Chen, Jianfeng Li, Guanghui Tian, Xudong Gong, Zhen Wang, Rongxia Zhang, Yongjian Liu, Hualiang Jiang
-
Patent number: 11427593Abstract: The present invention relates to a bromodomain inhibitor. Provided are a compound represented by general formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, atropisomer, racemate, polymorph, solvate, or isotopically labeled compound (including deuterium substitution) thereof, a preparation method of the same, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof.Type: GrantFiled: January 11, 2019Date of Patent: August 30, 2022Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Suzhou Suplead Life Sciences Co., Ltd.Inventors: Bing Zhou, Cheng Luo, Zizhou Li, Yaxi Yang, Shijie Chen, Hong Ding, Hualiang Jiang, Gang Qiao, Xinjun Wang, Senhao Xiao
-
Patent number: 11406651Abstract: The present invention relates to the application of mannuronic diacid oligosaccharide composition in the treatment of vascular dementia.Type: GrantFiled: June 28, 2019Date of Patent: August 9, 2022Assignees: GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCESInventors: Meiyu Geng, Xianliang Xin, Xiaoguang Du, Zhenqing Zhang, Jian Ding
-
Patent number: 11406659Abstract: The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of inflammation.Type: GrantFiled: June 28, 2019Date of Patent: August 9, 2022Assignees: GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCESInventors: Meiyu Geng, Xianliang Xin, Zhenqing Zhang, Jian Ding